IL77186D0 - Pharmaceutical insulin composition - Google Patents

Pharmaceutical insulin composition

Info

Publication number
IL77186D0
IL77186D0 IL7718685A IL7718685A IL77186D0 IL 77186 D0 IL77186 D0 IL 77186D0 IL 7718685 A IL7718685 A IL 7718685A IL 7718685 A IL7718685 A IL 7718685A IL 77186 D0 IL77186 D0 IL 77186D0
Authority
IL
Israel
Prior art keywords
insulin composition
pharmaceutical insulin
pharmaceutical
composition
Prior art date
Application number
IL7718685A
Original Assignee
Touitou Elka
Rubinstein Arnold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Touitou Elka, Rubinstein Arnold filed Critical Touitou Elka
Priority to IL7718685A priority Critical patent/IL77186D0/en
Publication of IL77186D0 publication Critical patent/IL77186D0/en

Links

IL7718685A 1985-11-29 1985-11-29 Pharmaceutical insulin composition IL77186D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL7718685A IL77186D0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IL7718685A IL77186D0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition
US06/934,741 US4910021A (en) 1985-11-29 1986-11-25 Targeted enternal delivery system
AT86309305T AT81287T (en) 1985-11-29 1986-11-28 On target organ acting enteral delivery system.
JP61282174A JP2633843B2 (en) 1985-11-29 1986-11-28 Administration system to the gut of a target
EP86309305A EP0225189B1 (en) 1985-11-29 1986-11-28 Targeted enteral delivery system
DE19863686936 DE3686936T2 (en) 1985-11-29 1986-11-28 On target organ acting enteral delivery system.
ES86309305T ES2035821T3 (en) 1985-11-29 1986-11-28 Enterica directed system administration.
DE19863686936 DE3686936D1 (en) 1985-11-29 1986-11-28 On target organ acting enteral delivery system.

Publications (1)

Publication Number Publication Date
IL77186D0 true IL77186D0 (en) 1986-04-29

Family

ID=11056458

Family Applications (1)

Application Number Title Priority Date Filing Date
IL7718685A IL77186D0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition

Country Status (7)

Country Link
US (1) US4910021A (en)
EP (1) EP0225189B1 (en)
JP (1) JP2633843B2 (en)
AT (1) AT81287T (en)
DE (2) DE3686936D1 (en)
ES (1) ES2035821T3 (en)
IL (1) IL77186D0 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
ES2045276T3 (en) * 1988-07-21 1994-01-16 Hoffmann La Roche Insulin preparation
JP2792862B2 (en) * 1988-07-30 1998-09-03 寛治 高田 Oral enteric agent
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
EP0386967B1 (en) * 1989-03-10 1995-07-12 Yamanouchi Pharmaceutical Co., Ltd. A drug-release controlling coating material for long acting formulations
DE3919982A1 (en) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Oral lipid pharmaceutical form
EP0414080B1 (en) * 1989-08-21 1994-02-16 F. Hoffmann-La Roche Ag Non-parenteral pharmaceutical compositions for insulin
EP0422290A1 (en) * 1989-10-09 1991-04-17 Eli Lilly And Company Novel drug delivery system
IT1237197B (en) * 1989-11-16 1993-05-26 Sclavo Spa Pharmaceutical formulations and anhydrous dosage forms for rectal administration of calcitonin.
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
JPH05507948A (en) * 1990-04-18 1993-11-11
JP3249147B2 (en) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Physiologically active protein-containing oral formulation
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JPH064531B2 (en) * 1990-06-04 1994-01-19 アイセロ化学株式会社 Large intestine disintegrating hard capsules
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes
FR2673376A1 (en) * 1991-03-01 1992-09-04 Lefesvre Andre A pharmaceutical composition for the treatment of sarcoma tumors.
EP0517412A1 (en) * 1991-06-03 1992-12-09 MERCK SHARP & DOHME LTD. Pharmaceutical formulations of a benzodiazepine
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JP2650578B2 (en) * 1992-08-27 1997-09-03 日本エランコ株式会社 For hard capsule gelatin coating composition and readily soluble hard gelatin capsules
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
DE69420346D1 (en) * 1993-03-25 1999-10-07 Kao Corp Dermatological preparations and new benzoic acid derivatives
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra The polypeptide formulation for inhalation further comprising an enhancer compound
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
AU7273494A (en) * 1993-09-01 1995-03-22 Pfizer Inc. Pharmaceutical compositions containing anionic surfactants
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4329503A1 (en) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmaceutical preparations for the targeted treatment of Crohn's disease and ulcerative colitis
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
SE9400918L (en) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabilized composition for oral administration of peptides
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
WO1996019198A1 (en) 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
JP2001524131A (en) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク Stable oral pharmaceutical dosage form
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
DE69938190T2 (en) 1998-10-15 2009-03-05 Novartis Vaccines and Diagnostics, Inc., Emeryville Genes with changed expression in metastic breast or thick-darm cancer cells
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
JP2000247911A (en) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc Absorption promoter for large intestine
JP4854115B2 (en) * 1999-03-12 2012-01-18 エイシカ ファーマシューティカルス リミテッド Stable formulation for anhydrous paroxetine
ES2235854T3 (en) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Disodium salts, monohydrates and solvates ethanolic for delivering active agents.
EP1197228A4 (en) 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co Medicinal compositions for treating colorectal cancer
JP5250168B2 (en) 2000-01-10 2013-07-31 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Differentially expressed genes in breast cancer
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
AU2002352988A1 (en) * 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Pipette configurations and arrays thereof for measuring cellular electrical properties
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2005002549A1 (en) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
EP1658089A4 (en) * 2003-08-27 2007-03-14 Vecta Ltd Compositions for treating pathologies that necessitate suppression of gastric acid secretion
CN1882316A (en) * 2003-09-19 2006-12-20 宾韦斯特医药公司 Delayed release dosage forms
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
ES2407465T3 (en) 2004-03-29 2013-06-12 Galpharma Co., Ltd. New modified galectin 9 protein and its use
WO2005117951A1 (en) * 2004-06-02 2005-12-15 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
CN1296098C (en) * 2004-09-29 2007-01-24 薛南荣 Oral insulin protecting agent
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
JP2009542605A (en) * 2006-07-06 2009-12-03 アレス トレーディング ソシエテ アノニム Anilino-pyrimidine oral pharmaceutical composition, process for its preparation and use thereof
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (en) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
JP2012504445A (en) * 2008-10-02 2012-02-23 フジフィルム・マニュファクチュアリング・ヨーロッパ・ベスローテン・フエンノートシャップ Antimicrobial coating
EP2762150A1 (en) * 2009-03-12 2014-08-06 Nordic Bioscience A/S Treatment of Diabetes and Metabolic Syndrome
JP5660037B2 (en) * 2009-05-18 2015-01-28 Jsr株式会社 Radiation sensitive resin composition
US8663671B2 (en) 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013031949A1 (en) * 2011-09-02 2013-03-07 富士フイルム株式会社 Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
AU2014239683B2 (en) 2013-03-15 2018-05-17 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2997915A1 (en) 2015-09-15 2017-03-23 C.B. Fleet Company, Incorporated Bisacodyl compositions and delivery apparatus
JP2019506383A (en) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド Formulations and methods for treating ulcerative colitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617671C3 (en) * 1967-03-07 1980-07-03 A. Nattermann & Cie Gmbh, 5000 Koeln
DE1924647B2 (en) * 1969-05-14 1974-11-28 Sanol-Arzneimittel Dr. Schwarz Gmbh, 4019 Monheim
US4022889A (en) * 1974-05-20 1977-05-10 The Upjohn Company Therapeutic compositions of antibiotic U-44,590 and methods for using the same
US4031215A (en) * 1974-11-11 1977-06-21 Kaken Chemical Co., Ltd. Streptovaricinone C derivatives as antibiotics
US4042688A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of providing high-protein nutrition by the oral administration of a predigested protein composition
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
JPS6346727B2 (en) * 1980-03-07 1988-09-19 Intaretsukusu Risaachi Corp
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
EP0037943B1 (en) * 1980-03-31 1985-08-14 Teijin Limited Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
SE8003805L (en) * 1980-05-21 1981-11-22 Haessle Ab A pharmaceutical formulation forbettrade utlosningsegenskap
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DE3046028A1 (en) * 1980-12-06 1982-07-15 Luk Lamellen & Kupplungsbau diaphragm pump
JPS6332041B2 (en) * 1981-03-09 1988-06-28 Hokko Chem Ind Co
ZA8205384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS649293B2 (en) * 1983-09-01 1989-02-16 Terumo Corp
JPH03852B2 (en) * 1983-11-01 1991-01-09 Terumo Corp
JPH0324452B2 (en) * 1984-04-11 1991-04-03 Terumo Corp

Also Published As

Publication number Publication date
EP0225189B1 (en) 1992-10-07
DE3686936T2 (en) 1993-04-29
JPS62195324A (en) 1987-08-28
JP2633843B2 (en) 1997-07-23
EP0225189A2 (en) 1987-06-10
EP0225189A3 (en) 1987-12-16
US4910021A (en) 1990-03-20
ES2035821T3 (en) 1993-05-01
AT81287T (en) 1992-10-15
DE3686936D1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
AU586276B2 (en) Multiple dosage syringe
GB2193894B (en) Medical syringe
GB2219585B (en) Pharmaceutical composition
DE3572767D1 (en) Pharmaceutical composition
GB2204792B (en) Pharmaceutical composition
AU586851B2 (en) Syringe
GB2153678B (en) Pharmaceutical composition
JPS61251700A (en) Insulin receptor
JPS61171422A (en) Medicinal composition
EP0127535A3 (en) Pharmaceutical compositions containing insulin
GB8521350D0 (en) Analgesic composition
EP0173990A3 (en) External pharmaceutical composition
JPS6187684A (en) Diazepine-containing medicinal composition
JPS62207221A (en) Improved administration of insulin
IE59777B1 (en) Medicaments
JPS63146815A (en) Ibuprofen-containing medicinal composition
JPS61286321A (en) Oral medicinal composition
JPS62185018A (en) Medicinal composition
GB8619566D0 (en) Drug particles
PH22480A (en) New sulphonylaminoethyl compounds and pharmaceutical compositions containing these compounds
PT83052A (en) Controlled release pharmaceutical composition
GB8518979D0 (en) Pharmaceutical preparation
GB8412357D0 (en) Pharmaceutical composition
EP0192263A3 (en) Readily absorbable pharmaceutical composition
GB2174904B (en) Vasculoprotecting pharmaceutical compositions